← All trials
NCT06152172
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 29, 2024
- Primary completion
- Feb 29, 2028
- Completion date
- Feb 29, 2028
- First posted
- Nov 30, 2023
- Last posted
- Dec 19, 2023
- Enrollment
- 24
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of PennsylvaniaLead sponsor
- University of PennsylvaniaSponsor investigator
- Kyverna TherapeuticsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.